Skip to Main Content

Henry G. Grabowski

Academic Advisor
Duke University
To contact Henry G. Grabowski, please email Stephanie Schwartz at Stephanie.Schwartz@brattle.com or call +1.617.864.7900

Dr. Grabowski is a Professor of Economics, member of the faculty for the Health Sector Management Program, and Director of the Program in Pharmaceuticals and Health Economics at Duke University.

Dr. Grabowski is Professor of Economics, member of the faculty for the Health Sector Management Program, and Director of the Program in Pharmaceuticals and Health Economics at Duke University. He has published numerous articles, books and studies on the pharmaceutical industry with his principal research involving the economics of the innovation process, business regulation, industrial organization, and international comparative analyses. He has served as advisor and consultant to the National Academy of Sciences, the Institute of Medicine, the Federal Trade Commission, the General Accounting Office and the Office of Technology Assessment.

He has held visiting scholar appointments at the International Institute of Management in Berlin, the Health Care Financing Administration in Washington, the Office of Health Economics, and the Centre for Medicines Research in London. Dr. Grabowski is a member of a number of professional organizations including the American Council on Science and Health and the American Enterprise Institute for Public Policy Research. He serves as an associate editor for The Quarterly Review of Economics and Finance and the Journal of Research in Pharmaceutical Economics.

Publications
Report
Brief of Antitrust Economists as Amicus Curiae in Re: Wellbutrin XL Antitrust Litigation
May 12, 2016
Prepared for the United States Court of Appeals for the Third Circuit
News & Events
May 12, 2016
Brattle Economist Contributes to Amicus Brief in Wellbutrin XL Antitrust Litigation

Brattle Principal Steven Herscovici recently contributed to an amicus brief in support of defendant-appellees including SmithKline Beecham Corporation in Re: Wellbutrin XL Antitrust Litigation, an antitrust case currently before the U.S. Court of Appeals for the Third Circuit.